Xbrane Biopharma AB: Notice of extra general meeting in Xbrane Biopharma AB

Press release
2018-03-16

The shareholders of Xbrane Biopharma AB, reg. no. 556749-2375, (the “Company”), are hereby convened to an extra general meeting to be held on Tuesday 3 April 2018, at 17.30 p.m. at Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm. The doors to the meeting will open at (…)

Xbrane Biopharma releases year-end report for 2017

Press release
2018-02-28

Xbrane Biopharma AB’s (publ.) (“Xbrane”) year-end report for 2017 is now available on the Company’s website, www.xbrane.com.

Financial summary fourth quarter 2017

• Revenue amounted to SEK 9,535 thousand (-).
• Gross margin amounted to 24% (-).
• EBITDA amounted to  (…)

Xbrane Biopharma publicerar bokslutskommuniké för 2017

Pressmeddelande
2018-02-28

Xbrane Biopharma ABs (publ.) (“Xbrane”) bokslutskommuniké för 2017 finns från och med idag tillgänglig på bolagets webbsida, www.xbrane.com.

Finansiell översikt fjärde kvartalet 2017

• Nettoomsättning uppgick till 9 535 TSEK (-).
• Bruttomarginalen uppgick till 24% (-). (…)

Xbrane Biopharma ingår utlicenseringsavtal med CR Pharma för Spherotide i Kina

Pressmeddelande
2018-02-06

Xbrane Biopharma (publ.) (“Xbrane”) och China Resource Pharmaceutical Group Limited (“CR Pharma”) har ingått ett utlicenseringsavtal som ger CR Pharma exklusiva rättigheter att marknadsföra och sälja Spherotide (“Triptorelin, en GnRH analog i injicerbar depå-formulering) (…)

Xbrane Biopharma signs license agreement with CR Pharma for Spherotide in China

Press release
2018-02-06

Xbrane Biopharma (publ.) (“Xbrane”) and China Resource Pharmaceutical Group Limited (“CR Pharma”) have entered into a license agreement which gives CR Pharma exclusive rights to market and sell Spherotide (Triptorelin, a GnRH analogue in a parenteral depot formulation) in  (…)

Serendipity Ixora proposes distribution of its Xbrane shares to its shareholders, after which Serendipity Group becomes the largest shareholder in Xbrane if the distribution is executed

Press release
2017-12-22

Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) informs that the Company’s largest shareholder Serendipity Ixora AB (“Serendipity Ixora”), intends to distribute all its shares in Xbrane to its shareholders. After the distribution that is expected to take place afte (…)

Xbrane Biopharmas huvudägare Serendipity Group ställer ut en kreditfacilitet på 50 MSEK till bolaget

Pressmeddelande
2017-12-22

Xbrane Biopharma AB (publ) (“Xbrane” eller “Bolaget”) har idag fått utställt en kreditfacilitet från Serendipity Group AB (“Serendipity Group”) på 50 MSEK (“Kreditfaciliteten”). Kreditfaciliteten finns tillgänglig för Bolaget under 18 månader.

Kreditfaciliteten
Kredit (…)

Xbrane Biopharma largest shareholder Serendipity Group issues a credit facility of SEK 50 million to the company

Press release
2017-12-22

Xbrane Biopharma AB (publ) (“Xbrane” or the “Company”) has today got issued a credit facility from Serendipity Group AB (“Serendipity Group”) of SEK 50 million (the “Credit Facility”). The Credit Facility can be utilized by the Company over a period of 18 months.

The C (…)